Lead

U.S. President Donald Trump has given generic pharmaceutical companies a two-year window to establish manufacturing facilities in the United States, warning that products imported after August 2028 could face tariffs of up to 200%. The announcement, made on Wednesday (July 22, 2026) through a social media post, has significant implications for India, which sends more than a third of its pharmaceutical exports to the U.S.

While Indian drugmakers sought to strike a cautious note, they warned that higher tariffs would ultimately increase medicine costs for American consumers. Mr. Trump said the measure is intended to encourage generic drug production in the U.S. and reduce dependence on overseas supply chains.

Coverage Comparison

The Hindu's report focused on the impact on India's pharmaceutical exports, quoting industry executives and noting the reaction of Indian pharmaceutical stocks. The report highlighted that the Nifty Pharma index fell 1.31%, with 18 of its 20 constituent companies closing lower. Industry executives largely adopted a wait-and-watch approach, while reiterating that any additional costs would likely be passed on to consumers.

Key Claims

  • U.S. President Donald Trump announced a two-year window for generic pharmaceutical companies to establish manufacturing facilities in the United States. Products imported after August 2028 could face tariffs of up to 200%.
  • India sends more than a third of its pharmaceutical exports to the U.S.
  • Indian drugmakers warned that higher tariffs would ultimately increase medicine costs for American consumers.
  • The policy aims to encourage generic drug production in the U.S. and reduce dependence on overseas supply chains.
According to the Global Trade Research Initiative (GTRI), India is among the countries most exposed to the proposed measure. India exported pharmaceutical products worth $25.8 billion in 2025, of which $9.7 billion, or 37.7%, went to the United States, its largest overseas market. Indian firms account for nearly 47% of all generic prescriptions dispensed in the U.S., making India the largest supplier of affordable generic medicines.

The U.S. imported pharmaceutical products worth $213 billion in 2025, including $94.1 billion worth of finished medicines sold in retail packs.

Dr. Reddy's Laboratories Chief Executive Officer Erez Israeli was quoted as saying, "It's not practical to move operations like that to the U.S. overnight. If tariffs are imposed, we will have to raise prices." He added that the company was not planning any immediate changes and noted that policy positions could evolve over time.

Building a fully domestic pharmaceutical supply chain in the U.S. would require significant investment and would almost certainly lead to higher medicine prices, according to the report.

Mr. Trump said that effective August 1, 2026, all generic drugs brought into the United States will continue to have a tariff of zero per cent for a two-year period, after which the tariff will be raised to 100% for a one-year period, and 200% thereafter. The policy, he added, is aimed at reshoring pharmaceutical manufacturing while preserving existing arrangements for patented and innovative medicines.